Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …

Background Patients with prostate cancer who have high-risk biochemical recurrence have
an increased risk of progression. The efficacy and safety of enzalutamide plus androgen …

Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …

Background Darolutamide is a structurally unique androgen-receptor antagonist that is
under development for the treatment of prostate cancer. We evaluated the efficacy of …

The therapeutic landscape of prostate cancer has been transformed over the last decade by
new therapeutics, advanced functional imaging, next-generation sequencing, and better use …

Background Injectable luteinizing hormone–releasing hormone agonists (eg, leuprolide) are
the standard agents for achieving androgen deprivation for prostate cancer despite the initial …

Abiraterone treats metastatic castrate-resistant prostate cancer by inhibiting CYP17A, an
enzyme for testosterone auto-production. With standard dosing, evolution of resistance with …

Background Nearly one-third of patients with prostate cancer (PCa) experience biochemical
recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant …

Many effective drugs for metastatic and/or advanced-stage cancers have been developed
over the past decade, although the evolution of resistance remains the major barrier to …